XML 62 R29.htm IDEA: XBRL DOCUMENT v3.22.4

Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregated Revenue

The following table presents our disaggregated revenue for the periods presented (in thousands):

		Year Ended December 31,
		2022				2021				2020
Immune Medicine revenue
Service revenue		$	31,777			$	24,482			$	12,207
Collaboration revenue			66,387				63,651				53,526
Total Immune Medicine revenue			98,164				88,133				65,733
MRD revenue
Service revenue			81,144				56,211				30,149
Regulatory milestone revenue			6,000				10,000				2,500
Total MRD revenue			87,144				66,211				32,649
Total revenue		$	185,308			$	154,344			$	98,382

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration